Lucijanić, M., Bušić, N., Stojić, J., Barišić Jaman, M., Zagorec, N., Lazibat, K. ... Baršić, B. (2023). Proton pump inhibitors use prior to COVID-19 hospitalization is associated with higher C lostridioides difficile infection rate. Expert Opinion on Drug Safety, 22. (12), 1265-1270. doi: 10.1080/14740338.2023.2234821
Lucijanić, Marko, et al. "Proton pump inhibitors use prior to COVID-19 hospitalization is associated with higher C lostridioides difficile infection rate." Expert Opinion on Drug Safety, vol. 22, br. 12, 2023, str. 1265-1270. https://doi.org/10.1080/14740338.2023.2234821
Lucijanić, Marko, Nikolina Bušić, Josip Stojić, Mislav Barišić Jaman, Nikola Zagorec, Karla Lazibat, Antica Pasarić, et al. "Proton pump inhibitors use prior to COVID-19 hospitalization is associated with higher C lostridioides difficile infection rate." Expert Opinion on Drug Safety 22, br. 12 (2023): 1265-1270. https://doi.org/10.1080/14740338.2023.2234821
Lucijanić, M., et al. (2023) 'Proton pump inhibitors use prior to COVID-19 hospitalization is associated with higher C lostridioides difficile infection rate', Expert Opinion on Drug Safety, 22(12), str. 1265-1270. doi: 10.1080/14740338.2023.2234821
Lucijanić M, Bušić N, Stojić J, Barišić Jaman M, Zagorec N, Lazibat K, i sur.. Proton pump inhibitors use prior to COVID-19 hospitalization is associated with higher C lostridioides difficile infection rate. Expert Opinion on Drug Safety [Internet]. 10.07.2023. [pristupljeno 21.10.2024.];22(12):1265-1270. doi: 10.1080/14740338.2023.2234821
M. Lucijanić, et al., "Proton pump inhibitors use prior to COVID-19 hospitalization is associated with higher C lostridioides difficile infection rate", Expert Opinion on Drug Safety, vol. 22, br. 12, str. 1265-1270, Srpanj 2023. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:861487. [Citirano: 21.10.2024.]